Cargando…
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-densit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168550/ https://www.ncbi.nlm.nih.gov/pubmed/30279504 http://dx.doi.org/10.1038/s41598-018-33058-x |
_version_ | 1783360372292452352 |
---|---|
author | Han, Ji Soo Kim, Kyu Jung, Youngae Lee, Jae-Hwan Namgung, June Lee, Hae-Young Suh, Jon Hwang, Geum-Sook Lee, Sang-Hak |
author_facet | Han, Ji Soo Kim, Kyu Jung, Youngae Lee, Jae-Hwan Namgung, June Lee, Hae-Young Suh, Jon Hwang, Geum-Sook Lee, Sang-Hak |
author_sort | Han, Ji Soo |
collection | PubMed |
description | In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-density lipoprotein-cholesterol targets, but had triglyceride and high-density lipoprotein-cholesterol levels ≥150 mg/dL and <50 mg/dL, respectively, were randomized to receive atorvastatin 20 mg or atorvastatin 10 mg/fenofibric acid 135 mg for 12 weeks. Metabolite profiling of serum was performed and changes in metabolites after drug treatment in the two groups were compared. Analysis was performed using patients’ samples obtained before and after treatment. Of 89 screened patients, 37 who met the inclusion criteria were randomized, and 34 completed the study. Unlike that in the dose-escalation group, distinct clustering of both lipid and aqueous metabolites was observed in the combination group after treatment. Most lipid metabolites of acylglycerols and many of ceramides decreased, while many of sphingomyelins increased in the combination group. Atorvastatin dose escalation modestly decreased lysophosphatidylcholines; however, the effect of combination therapy was variable. Most aqueous metabolites decreased, while l-carnitine remarkably increased in the combination group. In conclusion, the atorvastatin/fenofibric acid combination induced distinct metabolite clustering. Our results provide comprehensive information regarding metabolic changes beyond conventional lipid profiles for this combination therapy. |
format | Online Article Text |
id | pubmed-6168550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61685502018-10-05 Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin Han, Ji Soo Kim, Kyu Jung, Youngae Lee, Jae-Hwan Namgung, June Lee, Hae-Young Suh, Jon Hwang, Geum-Sook Lee, Sang-Hak Sci Rep Article In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-density lipoprotein-cholesterol targets, but had triglyceride and high-density lipoprotein-cholesterol levels ≥150 mg/dL and <50 mg/dL, respectively, were randomized to receive atorvastatin 20 mg or atorvastatin 10 mg/fenofibric acid 135 mg for 12 weeks. Metabolite profiling of serum was performed and changes in metabolites after drug treatment in the two groups were compared. Analysis was performed using patients’ samples obtained before and after treatment. Of 89 screened patients, 37 who met the inclusion criteria were randomized, and 34 completed the study. Unlike that in the dose-escalation group, distinct clustering of both lipid and aqueous metabolites was observed in the combination group after treatment. Most lipid metabolites of acylglycerols and many of ceramides decreased, while many of sphingomyelins increased in the combination group. Atorvastatin dose escalation modestly decreased lysophosphatidylcholines; however, the effect of combination therapy was variable. Most aqueous metabolites decreased, while l-carnitine remarkably increased in the combination group. In conclusion, the atorvastatin/fenofibric acid combination induced distinct metabolite clustering. Our results provide comprehensive information regarding metabolic changes beyond conventional lipid profiles for this combination therapy. Nature Publishing Group UK 2018-10-02 /pmc/articles/PMC6168550/ /pubmed/30279504 http://dx.doi.org/10.1038/s41598-018-33058-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Han, Ji Soo Kim, Kyu Jung, Youngae Lee, Jae-Hwan Namgung, June Lee, Hae-Young Suh, Jon Hwang, Geum-Sook Lee, Sang-Hak Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title | Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title_full | Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title_fullStr | Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title_full_unstemmed | Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title_short | Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin |
title_sort | metabolic alterations associated with atorvastatin/fenofibric acid combination in patients with atherogenic dyslipidaemia: a randomized trial for comparison with escalated-dose atorvastatin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168550/ https://www.ncbi.nlm.nih.gov/pubmed/30279504 http://dx.doi.org/10.1038/s41598-018-33058-x |
work_keys_str_mv | AT hanjisoo metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT kimkyu metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT jungyoungae metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT leejaehwan metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT namgungjune metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT leehaeyoung metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT suhjon metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT hwanggeumsook metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin AT leesanghak metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin |